Evaluation of Immunohistochemical Standing for BRAF (V600E) in Malignant Melanoma

DOI

Bibliographic Information

Other Title
  • 悪性黒色腫における BRAF（V600E） 免疫染色の有用性の検討

Search this article

Description

<p>A 68-year-old woman presented with a black tumor on her right sole for 11 years, and it had gradually increased in size from 3 years ago. We performed skin biopsy and PET-CT, and diagnosed her with malignant melanoma (c Stage IV). We also diagnosed her with a BRAFV600E mutation via BRAF gene mutation analysis of her tumor tissue, and treatment with dabrafenib at 300 mg PO plus trametinib at 2mg PO daily was initiated. The combination of dabrafenib and trametinib led to a good response, but the metastatic lesion on the left gastrocnemius muscle slightly increased in size. BRAF immunohistochemical staining demonstrated a difference in the intensity of staining between the responsive region and non-responsive region. Thus, BRAF immunohistochemical staining is a useful method for evaluating BRAF-mutant malignant melanoma patients. Skin Research, 18 : 27-32, 2019 </p>

Journal

  • Hifu no kagaku

    Hifu no kagaku 18 (1), 27-32, 2019

    Meeting of Osaka Dermatological Association/Meeting of Keiji Dermatological Association

Keywords

Details 詳細情報について

Report a problem

Back to top